In another tragic incident, Sarepta Therapeutics (NASDAQ: SRPT) saw a second death in connection with its Duchenne muscular ...

Sarepta Therapeutics (NasdaqGS:SRPT) recently announced that its SRP-9003 gene therapy received a platform technology designation from the FDA, and updated safety protocols for ELEVIDYS in the UK.

Investing.com-- TD Cowen downgraded its rating on Sarepta Therapeutics Inc (NASDAQ: SRPT) and slashed its price target ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research ...

Another patient has died from acute liver failure after receiving Sarepta’s gene therapy for DMD ; After a quiet start to the ...

In this week’s edition of InnovationRx, we look at the dangers of RFK Jr.’s vaccine advisory committee, how Trump’s visa ban ...

I am upgrading Dyne Therapeutics stock to a 'Buy' rating due to promising late-stage DM1 and DMD drug candidates and ...

Diaylsis-technology maker Fresenius Medical Care could end up benefiting from blockbuster obesity drugs, according to its chief executive, contrary to concerns that such treatments could deplete ...

Recent health headlines spotlight Surgery Partners rejecting Bain Capital's offer, the U.S. betting on China's drug potential ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

The bank's head of blockchain solutions Philippe Meyer told the DigiAssets conference in London that it started advising on ...